Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (NCT02842086)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.
Who can join: Review the eligibility criteria below.
Location: Clinical Research Facility — Beverly Hills, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (93 Sites)
Showing the first 25 of 93 sites.
- Clinical Research Facility — Beverly Hills, California
- Clinical Research Facility — Los Angeles, California
- Clinical Research Facility — Los Angeles, California
- Clinical Research Facility — Newport Beach, California
- Clinical Research Facility — Oakland, California
- Clinical Research Facility — Sacramento, California
- Clinical Research Facility — Sacramento, California
- Clinical Research Facility — San Diego, California
- Clinical Research Facility — San Francisco, California
- Clinical Research Facility — San Francisco, California
- Clinical Research Facility — San Francisco, California
- Clinical Research Facility — Torrance, California
- Clinical Research Facility — Aurora, Colorado
- Clinical Research Facility — Denver, Colorado
- Clinical Research Facility — New Haven, Connecticut
- Clinical Research Facility — Washington D.C., District of Columbia
- Clinical Research Facility — Washington D.C., District of Columbia
- Clinical Research Facility — Fort Lauderdale, Florida
- Clinical Research Facility — Fort Lauderdale, Florida
- Clinical Research Facility — Ft. Pierce, Florida
- Clinical Research Facility — Miami, Florida
- Clinical Research Facility — Orlando, Florida
- Clinical Research Facility — Pensacola, Florida
- Clinical Research Facility — West Palm Beach, Florida
- Clinical Research Facility — Atlanta, Georgia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Pre-Exposure Prophylaxis of HIV-1 Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.